Wolfgang Liedtke

Translational Neuroscience - clinical trialing - therapeutics development - neurogenetics and molecular neurobiology target and biomarker discovery - pain medicine - neurology - psychiatry - general medicine

Tasked with driving global clinical development as it intersects with basic research, human genetics, outcomes research (RWD) and business development, my contributions have significantly influenced and accelerated Regeneron's clinical development agenda, with particular footprint in clinical trialing. I am adding and integrating visionary interdisciplinary focus across my own portfolio responsibilities in clinical neuroscience, so that they are embedded within the 360 of Regeneron's therapeutic interests. In June 2021, while continuing to drive global thought leadership in molecular physiology and how it feeds into clinical development, I organized and chaired an international symposium "20 years of TRPV4 - Exploring Science, Discovery and Future Directions". This meeting was endorsed and co-sponsored by the American Physiological Society, featuring 42 key faculty and attended by a global audience. In November 2023, I was elected to the American Clinical and Climatological Association, an 1884-founded medical honor society for very senior physician leaders, with limited active membership to 250. In May 2024, I was appointed Senior Advisor to the Davos Alzheimer's Collaborative, a global medical-scientific non-profit organization, born out of the World Economic Forum in 2019, with a goal of leading a global response to the daunting challenge of Alzheimer's Disease by building an innovation ecosystem for acceleration of breakthroughs in clinical development. Also, I remain affiliated with the Facial Pain Association (FPA) as an elected Board Member, Senior and Lead Neurologist on their Medical Advisory Board, and Chair of their nascent FPA Trigeminal Pain Patient Registry. Also affiliated long-term with the Facial Pain Research Foundation, I support both non-profits which are providing invaluable stewardship to a global community of patients suffering from one of the worst forms of pain.

Senior leadership role driving interdisciplinary synergies between molecular physiology and medicine, leading independently-supported basic science research campaigns by infusing out-of-the-box ideas AND implementing them, mobilizing and leading corresponding clinical operations and integrating these into collaborative suprastructures, Duke-intern and -externally. Co-mentored by Bob Lefkowitz during initial years, I continued my interrogation of TRPV4 ion channel function, currently the most referenced scholar in this field, and made foundational discoveries of gene regulation of KCC2 (neuronal chloride transporter), with key relevance for neuroprotection. In clinics, I founded two uniquely interdisciplinary and highly popular clinical operations providing holistic, science-guided and empathetic care for patients with chronic head-face pain including trigeminal neuralgia, refractory migraines, chronic refractory pain in general, and pain in the context of challenging comorbidities from across the medical spectrum - and dentistry. Clinical trialing with DCRI. For my scientific accomplishments, I was awarded a Klingenstein Fellowship of the Klingenstein Fund (NYC; only Ebert Clinical Scholar), a Harrington Discovery Institute Scholar-Innovator Award of the Harrington Discovery Institute (Cleveland OH), and an Innovation-to-Impact Fellowship of Yale University. For my clinical stewardship, I was selected Distinguished Nominee of the Leonard Tow Award for Humanism in Medicine. I presented the Blaustein Pain Lecture at Johns Hopkins University. I also served as Project Lead for "Trigeminal Pain" in an interdisciplinary NIH pain program-project-grant, co-directed the popular course "Neurobiology of Disease" for 15+ years, and served on multiple hiring and promotion-and-tenure committees. Founded TRPblue, out of my laboratory, in 2017 (lead inventor on 7 awarded US patents). https://www.ncbi.nlm.nih.gov/myncbi/wolfgang.liedtke.1/bibliography/public/ h-index 80 1/25

Foundational discovery of the TRPV4 ion channel (then named vanilloid receptor-related osmotically activated channel, VR-OAC, landmark paper in Cell, October 2000, the first vertebrate osmoreceptor) as a distinguished member of the laboratory of Jeffrey M Friedman. After promotion to Assistant Professor and NIH K08 Clinical Scientist Award, I had two additional high-visibility papers in the PNAS on the role of TRPV4 in live animals, in mice and worms (Caenorhabditis elegans). Please see attached my TRPV4-papers out of Rockefeller.

Mentored by myelin-pioneer neuropathologist, Cedric S. Raine, my research focused on glial cell biology and glia's role in development and response to injury. I discovered the in-vivo function of the astrocytic marker, GFAP, my landmark paper published in NEURON (see attached), in addition I interrogated mechanisms of proteolytic injury to myelin in multiple sclerosis and MS preclinical models. I was supported by a highly selective Feodor Lynen Fellowship of the Alexander von Humboldt Society, Bonn, Germany, and won the Henry L Moses Award of Yeshiva University in 1998, 1st prize basic science..

General psychiatry in-, outpatient service; call rotation; Senior Resident, rotated through general acute psychiatry (locked, emergency-receiving ward), geronto-psychiatry locked ward; psychotherapy; addiction clinics including methadone substitution clinical care; outpatient on-call emergency neurologist and psychiatrist for the entire city of Essen